Can Boston Scientific Stock Surge 40% From Here?

Boston Scientific (BSX) has lost a third of its value year-to-date, including a single-session drop of 9% on March 30. For a company with a multi-year track record of double-digit revenue growth, that’s a significant drawdown. Is this a buying opportunity, or is the market correctly repricing a structurally weaker growth story?

We unpack this below.

Why Did BSX Fall Yesterday?

The immediate trigger was CHAMPION-AF trial data for the Watchman FLX device. The trial met its endpoints, but the device showed a slightly higher ischemic stroke rate versus standard blood thinners. This was enough for Raymond James to downgrade the stock and cut its target from $97 to $88.

The broader year-to-date decline reflects compounding issues:

• Despite beating Q4 2025 estimates on revenue ($5.29B) and EPS ($0.80), Q1 2026 guidance came in below expectations.
• The EP segment missed in Q4 ($890M vs. $933M expected), prompting securities class-action suits alleging management overstated growth prospects.
• The FDA flagged battery issues in the Accolade pacemaker line, resulting in a recall (affected population: 1.6 million people).
• The $14.5B Penumbra acquisition is diluting adjusted EPS by $0.06–$0.08 in its first full year.

Watchman and EP together drove over half of BSX’s year-over-year revenue growth. When both showed simultaneous deceleration, a stock priced for consistent execution repriced sharply.

Are The Fundamentals Holding Well?

Short answer – Yes. This becomes clear when comparing with competitors.

Revenue growth is the critical differentiator. BSX has grown revenues at 16.6% annually over three years, versus 4.9% for Medtronic (MDT) and 0.7% for Abbott (ABT). In the most recent quarter, BSX grew at 15.9%, nearly double Medtronic’s 8.7% and well ahead of Abbott’s 4.4%. See how Boston Scientific stacks up overall MDT, ABT, JNJ and others in the medtech industry.

Margins are comparable across the three player, with BSX holding a slight edge with operating margin of 19.8% versus Medtronic’s 18.6% and Abbott’s 18.2%. OCF (operating cash flow) margins follow the same pattern: 22.6%, 20.5%, and 21.6% respectively.

Balance sheet: BSX’s debt-to-equity of 11.1% is far lower than Medtronic’s 25.1% and close to Abbott’s 7.7%. The one weakness is cash-to-assets at 4.5%, versus Abbott’s 10.3% and Medtronic’s 9.2%, which may partly explain why negative headlines create outsized stock volatility.

Does That Mean BSX’s Valuation Is Attractive Now?

BSX stock trades at approximately 18.1x forward earnings, well below its three-year historical average of 26.5x. A reversion to 25x implies a price of approximately $87, consistent with Raymond James’ revised target and roughly 40% upside from current levels. See how BSX valuation has changed over time.

The peer comparison sharpens this. Abbott trades at 18.6x adjusted forward earnings and Medtronic at 15.3x. BSX at 18.1x is barely above Medtronic and below Abbott — two companies growing at a fraction of BSX’s rate. The market is currently pricing BSX’s earnings in line with its mature, slow-growth peers. That misalignment is the core of the opportunity.

So how can the multiples expand back to 25x? It requires the company to leverage its successful CHAMPION-AF presentation at ACC.26 to secure expanded, ‘shared decision-making’ guideline inclusions for WATCHMAN as a premier DOAC alternative. Simultaneously, BSX must deliver a positive AVANT GUARD readout to successfully expand FARAPULSE into first-line treatment for persistent AFib. Furthermore, management must validate their execution capabilities by proving the $14.5 billion Penumbra acquisition will swiftly transition from its projected first-year EPS dilution into an accretive earnings driver by year two.

So What Are The Risks?

(1) EP and Watchman growth settling structurally lower. If these segments stabilize in the high single digits, consensus earnings estimates need further revision, and the current 18x multiple isn’t as cheap as it appears.

(2) Recall litigation timeline. The 1.6 million unit recall is software-based, requiring device reprogramming rather than physical replacement, which meaningfully limits direct costs. Historical CRM recalls of comparable scale ran into the hundreds of millions in litigation, spread over five to ten years, and that seems manageable against $4.5B in annual operating cash flow. The harder variable is physician behavior. Market share lost to Abbott or Medtronic during the recall overhang is slow and expensive to recover.

(3) Penumbra integration. If costs exceed projections or revenue synergies delay, EPS dilution extends beyond the first year.

(4) Earnings revisions not complete. The guidance miss and EP underperformance suggest sell-side models haven’t fully reset. Further 2026–2027 estimate cuts could happen, which could pressure the stock in the near term before a floor is established.

The Bottom Line

At 18x forward adjusted earnings versus a historical average of 25x, BSX is trading at a discount to its own history and at parity with peers growing at a fraction of its rate. The recall liability is containable, Penumbra adds a meaningful growth vector, and a reversion to historical multiples implies approximately 40% upside.

For a long-term investor, the entry is attractive. The practical caveat is timing, as the earnings revisions and the litigation narrative will likely keep pressure on the stock for another quarter or two.

BSX is one example of a high-quality business that may be temporarily mispriced by the market. The ability to identify these situations and hold through near-term noise is what separates long-term compounding from short-term trading. But no single stock, however compelling, should carry a portfolio alone. A well-constructed portfolio absorbs single-stock volatility while continuing to compound on winners elsewhere. Consistently beating the market is difficult, but the Trefis High Quality (HQ) Portfolio demonstrates it is achievable. Built around 30 high-conviction stocks, the HQ strategy has historically outperformed the S&P 500, S&P Mid-cap, and Russell 2000.